News Out of Europe: Johnson & Johnson Buys Actelion
Johnson & Johnson is buying the Swiss biotech Actelion for $30 billion.
Here is a round-up of the news out of Europe.
Johnson & Johnson (JNJ) - Get Report has finalized a deal to buy Swiss biotech Actelion (ALIOF) . The $30 billion takeover will see Johnson & Johnson spin out Actelion's R&D unit into a separate business.
Unilever (UN) - Get Report has posted weaker-than-expected full-year earnings. The company's decline, mixed with a stronger pound, held down the FTSE 100.
Royal Bank of Scotland (RBS) - Get Report has set aside $3.8 billion in Department of Justice provisions, in anticipation of an upcoming settlement. RBS says provisions will not impact distributable reserves.
